FDA Approves VAXELIS™, Sanofi and Merck’s Pediatric Hexavalent Combination Vaccine

Source: www.news.sanofi.us The U.S. Food and Drug Administrator (FDA) has given its approval for Sanofi and Merck’s drug VAXELIS. This drug can be used as...

Boston Scientific Announces Recommended Offer to Acquire BTG plc.

MARLBOROUGH, Mass., Nov. 20, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offe

Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three...

SUZHOU, China, Dec. 16, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Incyte (NASDAQ:INCY) today announced that th

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Ph

MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of...

Source: globenewswire.com MacroGenics Inc. has announced positive results from SOPHIA, a Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is...

ViiV Healthcare Submits New Drug Application to US FDA for the...

ViiV HC submits New Drug Application to US FDA for first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV

DowDuPont Board Approves Separation Of DowDuPont’s Materials Science Division

DowDuPont (DWDP) said that its board has approved the separation of DowDuPont's Materials Science Division, which will become the new Dow on April 1. In connection with the separation, the DowDuPont board of directors declared a pro rata dividend of all of the outstanding shares of common stock of Dow Inc.

Dr Reddys Laboratories launches Tadalafil Tablets USP in US market |...

Read more about Dr Reddys Laboratories launches Tadalafil Tablets USP in US market on Business Standard. The Cialis brand and generic had U.S. sales of approximately $1.7 billion MAT for the most recent twelve months ending in January 2019 according to IMS Health.

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral...

ROCKLAND, Mass., March 29, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada

Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two...

DARMSTADT, Germany, January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editin